TD Cowen Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its price objective cut by analysts at TD Cowen from $116.00 to $94.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. TD Cowen’s price target points to a potential upside of 3.18% from the stock’s current price.

A number of other research analysts have also recently weighed in on BNTX. Truist Financial set a $155.00 price objective on shares of BioNTech in a report on Tuesday. BMO Capital Markets reduced their target price on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday. Morgan Stanley restated an “overweight” rating on shares of BioNTech in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. Finally, Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a research note on Monday, February 2nd. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $132.43.

BioNTech Trading Up 8.6%

NASDAQ BNTX traded up $7.21 during trading on Wednesday, hitting $91.10. The stock had a trading volume of 2,515,282 shares, compared to its average volume of 1,126,428. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.51 billion, a PE ratio of -34.64 and a beta of 1.51. The firm has a 50 day moving average price of $106.73 and a 200 day moving average price of $102.83. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

Institutional Investors Weigh In On BioNTech

Large investors have recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the first quarter worth $167,000. Envestnet Asset Management Inc. increased its holdings in BioNTech by 20.6% in the second quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock valued at $1,125,000 after buying an additional 1,808 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in BioNTech in the second quarter valued at $303,000. Finally, Profund Advisors LLC raised its stake in BioNTech by 3.6% in the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after buying an additional 149 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Strong balance sheet and pipeline: BioNTech reported €17.2B in cash and securities and outlined six late‑stage readouts and multiple oncology programs that management says derisk execution and support long‑term value creation. BioNTech corporate update and results
• Positive Sentiment: Potential upside from the co‑founders’ new venture: BioNTech will receive a minority stake in the new company and may earn milestone payments and royalties from contributed rights/technologies, creating optionality if next‑gen mRNA assets succeed. Co‑founders launch new mRNA venture
• Neutral Sentiment: Mixed quarter — EPS beat but revenue dynamics weak: BioNTech beat EPS estimates (reported ($0.39) vs. ($0.57) expected) and posted revenue of $1.06B (above consensus), but revenue is down ~24% YoY and adjusted losses were reported. Investors will parse beats vs underlying growth trends. Q4 2025 earnings highlights
• Neutral Sentiment: Analyst repositioning: Jefferies cut its price target (from $151 to $138) but kept a buy rating — signaling some analyst confidence on long‑term upside despite nearer‑term risks. Analyst PT change
• Negative Sentiment: Cofounders’ exit raises governance and execution concerns: Founders Ugur Sahin and Özlem Türeci will leave by end‑2026 to start a new company; BioNTech will transfer certain rights/tech, prompting investor worry about talent loss and strategic disruption. Reuters: founders to leave
• Negative Sentiment: Weaker FY2026 revenue guidance: Management cut 2026 revenue guidance to roughly €2.0–2.3B (below Street expectations), increasing near‑term growth concerns and pressuring sentiment. Full results and guidance
• Negative Sentiment: Regulatory/legal overhang: A plaintiff firm (Johnson Fistel) is investigating potential claims against BioNTech’s executives, adding legal risk and headline volatility. Johnson Fistel investigation notice
• Negative Sentiment: Immediate market reaction: Multiple outlets report a steep intraday share decline after the combined news of the founder exit and weaker outlook, reflecting selling pressure and short‑term sentiment deterioration. Market reaction coverage

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.